Fisher & Paykel Healthcare stock gets an RBC target lift

Published on 09/29/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fisher & Paykel Healthcare stock has an RBC target of NZD 52.00 after a September 16 upgrade. FY26 revenue grew 14.2 percent to NZD 2,308 million.

FPH, NZFAPE0001S2, Illustration mit AI erstellt.

Fisher & Paykel Healthcare stock was at NZD 45.54 on the NZX on September 29, 2026, while Investing.com reported that RBC raised its price target to NZD 52.00 from NZD 39.00 on September 16, 2026. The upgrade moved RBC's view from Sector Perform to Outperform and puts the target NZD 6.46 above the cited NZX price.

RBC raises target to NZD 52.00

RBC linked its upgrade to Fisher & Paykel Healthcare's hospital opportunity, arguing that the company has a large addressable market and relatively low penetration. The report also expects mid-to-high teens revenue growth and further operating leverage over the next several years, according to Investing.com.

The higher target comes with a valuation constraint. RBC said the shares trade at a premium to peers, making sustained growth and operating leverage important conditions for the target to remain credible.

FY26 revenue grows 14.2 percent

Fisher & Paykel Healthcare reported FY26 revenue of NZD 2,308 million, up 14.2 percent after 16.0 percent growth in the prior year, according to Alpha Insights on September 3, 2026. Hospital consumables grew 14.00 percent in constant currency, giving the business a second quantified growth engine beyond the group total.

Operating cash flow reached NZD 661 million in FY26, while free cash flow was NZD 466 million after NZD 195 million of capital expenditure, the same analysis reported. That cash generation supports capacity expansion and dividends while keeping the investment story tied to operating execution rather than external financing.

Half year results come in November

Fisher & Paykel Healthcare's investor calendar places the financial half year end on September 30, 2026, with the half year results announcement scheduled for November 2026, according to the company's investor page. The upcoming report will test whether hospital demand and consumables growth are tracking the expectations behind RBC's revised target.

NZX price stays near yearly high

On September 29, 2026, the NZX price of NZD 45.54 stood 0.68 percent below the 52-week high of NZD 45.85 and above the 52-week low of NZD 32.16. Fisher & Paykel Healthcare had a market capitalization of NZD 26.7 billion and trading volume of 551,701 shares on that date.